https://www.nasdaq.com/press-release/nikang-therapeutics-and-aveo-oncology-announce-a-clinical-trial-collaboration-and
https://www.nasdaq.com/press-release/aveo-oncology-highlights-recent-progress-and-2022-outlook-2022-01-04
https://www.nasdaq.com/press-release/aveo-oncology-announces-clinical-trial-collaboration-and-supply-agreement-with-merck
https://www.nasdaq.com/press-release/aveo-oncology-announces-participation-at-the-h.c.-wainwright-virtual-bioconnect-2022
https://www.nasdaq.com/press-release/aveo-oncology-announces-appointment-of-jeb-ledell-as-chief-operating-officer-2021-12
https://www.nasdaq.com/press-release/aveo-oncology-announces-participation-at-two-upcoming-virtual-investor-conferences-0
https://www.nasdaq.com/press-release/aveo-oncology-reports-third-quarter-2021-financial-results-and-provides-business
https://www.nasdaq.com/press-release/aveo-oncology-to-announce-third-quarter-2021-financial-results-and-host-conference
https://www.nasdaq.com/press-release/aveo-oncology-announces-ficlatuzumab-granted-fast-track-designation-by-the-u.s.-fda
https://www.nasdaq.com/press-release/aveo-oncology-announces-participation-at-two-upcoming-virtual-investor-conferences
https://www.nasdaq.com/press-release/aveo-oncology-reports-second-quarter-2021-financial-results-and-provides-business
https://www.nasdaq.com/press-release/aveo-oncology-to-announce-second-quarter-2021-financial-results-and-host-conference
https://www.nasdaq.com/press-release/aveo-oncology-to-host-key-opinion-leader-webinar-on-fotivdar-tivozanib-for-relapsed
https://www.nasdaq.com/press-release/aveo-oncology-to-host-key-opinion-leader-webinar-on-ficlatuzumab-in-head-and-neck
https://www.nasdaq.com/press-release/aveo-oncology-to-present-at-the-jefferies-2021-virtual-healthcare-conference-2021-05
https://www.nasdaq.com/press-release/aveo-oncology-announces-presentation-of-long-term-efficacy-follow-up-additional
https://www.nasdaq.com/press-release/aveo-oncology-announces-positive-results-from-randomized-phase-2-study-of
https://www.nasdaq.com/press-release/aveo-oncology-reports-first-quarter-2021-financial-results-and-provides-business
https://www.nasdaq.com/press-release/aveo-oncology-to-announce-first-quarter-2021-financial-results-and-host-conference
https://www.nasdaq.com/press-release/aveo-announces-appointment-of-kevin-cullen-m.d.-to-its-board-of-directors-2021-04-16
https://www.nasdaq.com/press-release/aveo-oncology-announces-addition-of-fotivdar-tivozanib-into-national-comprehensive
https://www.nasdaq.com/press-release/aveo-announces-closing-of-public-offering-of-common-stock-and-full-exercise-of-option
https://www.nasdaq.com/press-release/aveo-announces-pricing-of-%2448.0-million-public-offering-of-common-stock-2021-03-23
https://www.nasdaq.com/press-release/aveo-announces-proposed-public-offering-of-common-stock-2021-03-22
https://www.nasdaq.com/press-release/aveo-oncology-announces-u.s.-commercial-availability-of-fotivdar-tivozanib-for-the
https://www.nasdaq.com/press-release/aveo-oncology-reports-full-year-2020-financial-results-and-provides-business-update
https://www.nasdaq.com/press-release/aveo-oncology-to-regain-ex-north-american-rights-to-av-203-2021-03-15
https://www.nasdaq.com/press-release/aveo-oncology-announces-collaboration-with-bristol-myers-squibb-to-evaluate-fotivdar
https://www.nasdaq.com/press-release/aveo-oncology-announces-drawdown-of-%2420-million-tranche-under-hercules-debt-facility
https://www.nasdaq.com/press-release/aveo-announces-appointment-of-mike-ferraresso-to-chief-commercial-officer-2021-03-10
https://www.nasdaq.com/press-release/aveo-oncology-announces-u.s.-fda-approval-of-fotivdar-tivozanib-for-the-treatment-of
https://www.nasdaq.com/press-release/aveo-oncology-to-present-at-the-h.c.-wainwright-global-life-sciences-conference-2021
https://www.nasdaq.com/press-release/aveo-oncology-announces-participation-at-the-2021-svb-leerink-global-healthcare
https://www.nasdaq.com/press-release/aveo-oncology-announces-presentation-of-key-subgroup-and-quality-of-life-analyses
https://www.nasdaq.com/press-release/aveo-oncology-announces-commitment-for-an-incremental-%2410-million-loan-in-addition-to
https://www.nasdaq.com/press-release/aveo-oncology-announces-results-from-phase-1b-portion-of-deductive-study-of-tivozanib
https://www.nasdaq.com/press-release/aveo-oncology-highlights-recent-progress-and-2021-outlook-2021-01-07
https://www.nasdaq.com/press-release/aveo-oncology-announces-participation-at-two-upcoming-investor-conferences-2021-01-06
https://www.nasdaq.com/press-release/aveo-oncology-announces-webcast-of-presentation-at-the-39th-annual-j.p.-morgan
https://www.nasdaq.com/press-release/aveo-oncology-to-present-at-the-stifel-2020-virtual-healthcare-conference-2020-11-10
https://www.nasdaq.com/press-release/aveo-oncology-reports-third-quarter-2020-financial-results-and-provides-business
https://www.nasdaq.com/press-release/aveo-oncology-and-eusa-pharma-announce-annals-of-oncology-publication-of-data-from
https://www.nasdaq.com/press-release/aveo-oncology-announces-appointment-of-david-w.-crist-as-vice-president-of-sales-2020
https://www.nasdaq.com/press-release/aveo-oncology-announces-european-urology-publication-of-final-overall-survival-data
https://www.nasdaq.com/press-release/aveo-oncology-regains-full-global-rights-to-ficlatuzumab-2020-09-08
https://www.nasdaq.com/press-release/aveo-oncology-announces-participation-at-two-upcoming-investor-conferences-2020-09-03
https://www.nasdaq.com/press-release/aveo-oncology-announces-restructuring-of-existing-term-loan-with-closing-of-new
https://www.nasdaq.com/press-release/aveo-oncology-reports-second-quarter-2020-financial-results-and-provides-business
https://www.nasdaq.com/press-release/aveo-oncology-announces-%242.8m-development-milestone-earned-from-kyowa-kirin-2020-08
https://www.nasdaq.com/press-release/aveo-oncology-to-present-at-the-31st-annual-piper-jaffray-healthcare-conference-2019
https://www.nasdaq.com/press-release/aveo-oncology-to-present-at-the-2019-cantor-fitzgerald-global-healthcare-conference
https://www.nasdaq.com/press-release/aveo-oncology-and-eusa-pharma-announce-presentation-of-final-pfs-results-from-phase-2
